Apatinib Plus Chemotherapy Shows Clinical Activity in Advanced NSCLC: A Retrospective Study

Apatinib is an oral TKI with antiangiogenic properties, and it is currently approved for the treatment of advanced gastric cancer in China. This agent has also been tested in other human solid tumors, including non-small cell lung cancer (NSCLC). Since the combination of chemotherapy and an antiangi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Jing, Li, Xu Yong, Liang, Jing Bo, Wu, De, Peng, Li, Li, Xiaobing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cognizant Communication Corporation 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7848396/
https://www.ncbi.nlm.nih.gov/pubmed/29929572
http://dx.doi.org/10.3727/096504018X15288447760357

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7848396/
https://www.ncbi.nlm.nih.gov/pubmed/29929572
http://dx.doi.org/10.3727/096504018X15288447760357

Ejemplares similares